Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Revelation Biosciences, Inc. - Common Stock (NQ:REVB)

1.550 -0.100 (-6.06%)
Streaming Delayed Price Updated: 1:56 PM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Revelation Biosciences, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Nasdaq Grants Revelation Biosciences Inc. Continued Listing
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds
From Revelation Biosciences Inc.
Via Business Wire
News headline image
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)
From Revelation Biosciences Inc.
Via Business Wire
News headline image
Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference
From Revelation Biosciences Inc.
Via Business Wire
News headline image
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini
From Revelation Biosciences Inc.
Via Business Wire
News headline image
Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
From Revelation Biosciences Inc.
Via Business Wire
BioMedNewsBreaks – Revelation Biosciences Inc. (NASDAQ: REVB) Secures ~$6.2M in Public Offering
Via Investor Brand Network
News headline image
Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering
From Revelation Biosciences Inc.
Via Business Wire
News headline image
Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering
From Revelation Biosciences Inc.
Via Business Wire
News headline image
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
From Revelation Biosciences Inc.
Via Business Wire
News headline image
Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024
From Revelation Biosciences Inc.
Via Business Wire
News headline image
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Gemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical Studies
From Revelation Biosciences Inc.
Via Business Wire
News headline image
Revelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities Conference
From Revelation Biosciences Inc.
Via Business Wire
News headline image
Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors
From Revelation Biosciences Inc.
Via Business Wire
News headline image
Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023
From Revelation Biosciences Inc.
Via Business Wire
News headline image
REMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of Stockholders
From Revelation Biosciences Inc.
Via Business Wire
News headline image
Revelation Biosciences Inc. Announces Adjournment of 2023 Annual Meeting of Stockholders to July 7, 2023 and Additional Proposal
From Revelation Biosciences Inc.
Via Business Wire
News headline image
Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress
From Revelation Biosciences Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.